Rhythm Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rhythm Pharmaceuticals (RYTM).

Price Target Range — 10 Quarters

Analyst Consensus — 17 Analysts

2S.Buy

15Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$132Upside to Avg. PT+16.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	JP Morgan	Priyanka Grover	PT Raise	Overweight	$145→$146
Aug 5, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$142→$143
Aug 5, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$141→$155
Aug 5, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$155→$160
Jul 27, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$145
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$137→$141
Jun 16, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$143→$151
Jun 15, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$144→$155
May 7, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$140→$143
May 6, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$136→$137
May 6, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$143→$144
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$100→$105
Mar 20, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$131→$142
Mar 20, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$139→$149
Mar 20, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$152→$155
Mar 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$110→$100
Mar 17, 2026	Citigroup	Samantha Semenkow	PT Cut	Buy	$136→$131
Mar 17, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$140→$130
Mar 17, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$176→$152
Mar 17, 2026	B of A Securities	Tazeen Ahmad	PT Cut	Buy	$145→$139

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.

Benzinga Newsdesk

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

PRO
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

People Also Watch

People Also Watch

Benzinga

Benzinga

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PROCitigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PROCitizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

PROJP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

PRORBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

PRO
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

PRO
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

PRO
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

PRO
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141